Gemcabene

Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity[1][2][3].

Product Specifications

CAS Number

[183293-82-5]

Product Name Alternative

PD-72953

UNSPSC

12352211

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/gemcabene.html

Purity

99.91

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O

Molecular Formula

C16H30O5

Molecular Weight

302.41

References & Citations

[1]Mandema JW, et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J. 2005 Oct 7;7 (3) :E513-22.|[2]Srivastava RAK, et al. Gemcabene, a First-in-Class Hypolipidemic Small Molecule in Clinical Development, Attenuates Osteoarthritis and Pain in Animal Models of Arthritis and Pain. Front Pharmacol. 2018 May 11;9:471.|[3]Oniciu DC, et al. Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH. PLoS One. 2018 May 30;13 (5) :e0194568.